Stockscreener 앱 받기
0.00
100.00%
-3.65
시간 외 거래:
3.66
3.66
+
전일 마감가:
$3.65
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$381.02M
수익:
$234.04M
순이익/손실:
$-323.92M
주가수익비율:
0.00
EPS:
-3.8
순현금흐름:
$-223.46M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$3.66
52주 변동 폭
$0.00
$7.56
Revance Therapeutics Inc Stock (RVNC) Company Profile
명칭
Revance Therapeutics Inc
전화
(615) 724-7755
주소
1222 DEMONBREUN STREET, NASHVILLE, CA
RVNC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
0.00 | 381.02M | 234.04M | -323.92M | -223.46M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.22 | 117.23B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
665.46 | 72.75B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.02 | 38.65B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.99 | 34.69B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.50 | 27.45B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-01-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-08-16 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-22 | 개시 | Goldman | Buy |
| 2021-10-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | 재확인 | Needham | Buy |
| 2020-08-11 | 재개 | Mizuho | Buy |
| 2020-03-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-12-02 | 개시 | Goldman | Buy |
| 2019-10-30 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-02-15 | 개시 | Wells Fargo | Market Perform |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
| 2018-11-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2018-09-17 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | 재확인 | Mizuho | Buy |
| 2018-03-27 | 개시 | Needham | Buy |
| 2018-03-05 | 개시 | Goldman | Buy |
| 2018-01-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2017-12-06 | 개시 | Guggenheim | Buy |
| 2017-12-06 | 재확인 | Mizuho | Buy |
| 2017-11-27 | 개시 | Barclays | Overweight |
| 2017-11-17 | 개시 | Mizuho | Buy |
| 2017-08-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Revance Therapeutics Inc 주식(RVNC)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesRVNC - PR Newswire
Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors - GlobeNewswire
2025-02-11 | Shareholders that lost money on Revance Therapeutics, Inc. (RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC | Press Release - Stockhouse Publishing
2025-02-10 | Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky about Pending Class ActionRVNC | Press Release - Stockhouse Publishing
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
2025-02-10 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline | Press Release - Stockhouse Publishing
2025-02-10 | RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | Press Release - Stockhouse Publishing
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders - PR Newswire
Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
2025-02-09 | Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky | Press Release - Stockhouse Publishing
Deltec Asset Management LLC Makes New $304,000 Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - ETF Daily News
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by SG Americas Securities LLC - Defense World
Revance Therapeutics (NASDAQ:RVNC) Completes Merger with Crown Laboratories - Defense World
Crown Labs completes acquisition of Revance Therapeutics - MSN
Crown Laboratories Completes Acquisition of Revance Therapeutics - BioSpace
Major Aesthetics Industry Shakeup: Crown Labs Takes Over Revance in Strategic Power Move - StockTitan
Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance LawsuitRVNC - The Malaysian Reserve
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria
GLAZER CAPITAL, LLC Acquires Significant Stake in Revance Therap - GuruFocus.com
DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of - GlobeNewswire
Revance Therapeutics Finalizes Merger with Crown Laboratories - MSN
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Revance’s acquisition by Crown Laboratories completed - TipRanks
Major Aesthetics Deal: Crown Labs Acquires Revance as Shareholders Cash Out at Premium - StockTitan
The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Taking a Closer Look At Revance Therapeutics Inc (RVNC) Following Its Recent Trade - Knox Daily
Lawsuit Alert: Investors who lost money with shares of Revance - openPR
Revance Therapeutics sells to Crown Laboratories - The Business Journals
Revance Therapeutics Inc’s Shares Reel: -37.07% Quarterly Revenue Decline Amid 381.02M Market Cap - The InvestChronicle
Revance Therapeutics, Crown Laboratories Announce Expiration of Tender Offer -February 05, 2025 at 10:39 am EST - Marketscreener.com
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer - Marketscreener.com
Major Biotech Deal: Revance Shareholders Back Crown Labs Takeover with Massive 82% Support Rate - StockTitan
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Revance - GlobeNewswire
ForexTV | Small Business Resources - ForexTV.com
RVNC INVESTOR ALERT: Kirby McInerney LLP Notifies Revance Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit - yourbigsky.com
Levi & Korsinsky Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 – RVNC - yourbigsky.com
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your RightsRVNC - PR Newswire
RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
2025-02-03 | Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC | NDAQ:RVNC | Press Release - Stockhouse Publishing
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) - GuruFocus.com
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class ActionRVNC - PR Newswire
Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC - ACCESS Newswire
2025-02-02 | Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC | NDAQ:RVNC | Press Release - Stockhouse Publishing
2025-02-01 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline | NDAQ:RVNC | Press Release - Stockhouse Publishing
Mizuho maintains neutral on Revance, price target steady at $3.65 - MSN
Revance Therapeutics Inc (RVNC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.27%
5.10%
자본화:
|
볼륨(24시간):